AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22571890 — intervention group
Group type: COMPARATOR
Intervention: Control group (statistical treatment guidelines for AAA)
Number of subjects: 208
Study 19683469 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oVEMP and cVEMP test
Number of subjects: 32
Study 19683469 — intervention group
Group type: COMPARATOR
Intervention: Individual oVEMP and cVEMP tests
Number of subjects: 32
Study 17559755 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg)
Number of subjects: 294
Study 17559755 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine (60 mg)
Number of subjects: 294
Study 15212720 — intervention group
Group type: EXPERIMENTAL
Intervention: VLTS-589 (plasmid-expressing Del-1)
Number of subjects: 100
Study 15212720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12418673 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized PRP-T with DTP
Number of subjects: 284
Study 12418673 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid DTP/PRP-T formulation
Number of subjects: 284
Study 12418673 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid DTP/PRP-T formulation (Part 2)
Number of subjects: 284
Study 12418673 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of PRP-T/DTP
Number of subjects: 284
Study 12418673 — intervention group
Group type: COMPARATOR
Intervention: DTP alone
Number of subjects: 284
Study 9848776 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg/d)
Number of subjects: 9
Study 9848776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8090847 — intervention group
Group type: EXPERIMENTAL
Intervention: Research report with an example included (group 1)
Number of subjects: 69
Study 8090847 — intervention group
Group type: COMPARATOR
Intervention: Research report without an example (group 2)
Number of subjects: 69
Study 2589059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular lenses with ultraviolet absorbing chromophore
Number of subjects: 55
Study 2589059 — intervention group
Group type: COMPARATOR
Intervention: Standard posterior chamber intraocular lens
Number of subjects: 55
Study 31855498 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplements (vitamins A, C, and E; carotenoids; coenzyme Q10) before and during treatment
Number of subjects: 1134
Study 31855498 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 use before and during chemotherapy
Number of subjects: 1134
Study 31855498 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron use during chemotherapy
Number of subjects: 1134
Study 31855498 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin use
Number of subjects: 1134
Study 31058727 — intervention group
Group type: COMPARATOR
Intervention: Classical group (n=15)
Number of subjects: 30
Study 31058727 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezo group (n=15)
Number of subjects: 30
Study 28416405 — intervention group
Group type: EXPERIMENTAL
Intervention: SLEEP Inventory (Sex, Left heart failure, ESS, Enlarged neck, weight [in Pounds], Insulin resistance/diabetes, and National Institutes of Health Stroke Scale)
Number of subjects: 0
Study 28416405 — intervention group
Group type: COMPARATOR
Intervention: Berlin Questionnaire
Number of subjects: 0
Study 28416405 — intervention group
Group type: COMPARATOR
Intervention: Epworth Sleepiness Scale (ESS)
Number of subjects: 0
Study 28416405 — intervention group
Group type: COMPARATOR
Intervention: Snoring, Tiredness, Observed apnea, high blood Pressure, Body mass index, Age, Neck circumference, and Gender instrument
Number of subjects: 0
Study 28416405 — intervention group
Group type: COMPARATOR
Intervention: Sleep Apnea Clinical Score
Number of subjects: 0
Study 26162815 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient cardiac rehabilitation (Group 1)
Number of subjects: 834
Study 26162815 — intervention group
Group type: COMPARATOR
Intervention: No inpatient cardiac rehabilitation (Group 2)
Number of subjects: 834
Study 23381494 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mometasone furoate (MF) for 6 weeks
Number of subjects: 28
Study 23381494 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 28
Study 23381494 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mometasone furoate (MF)
Number of subjects: 28
Study 23381494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 21554040 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 0
Study 21554040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19356485 — intervention group
Group type: COMPARATOR
Intervention: Normal geometry
Number of subjects: 603
Study 19356485 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric remodeling
Number of subjects: 603
Study 19356485 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric hypertrophy
Number of subjects: 603
Study 19356485 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric hypertrophy
Number of subjects: 603
Study 19356485 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline LVMi increase
Number of subjects: 603
Study 19356485 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline RWT increase
Number of subjects: 603
Study 16226211 — intervention group
Group type: EXPERIMENTAL
Intervention: Operating the vehicle entertainment system
Number of subjects: 0
Study 16226211 — intervention group
Group type: EXPERIMENTAL
Intervention: Conducting a simulated hands-free mobile phone conversation
Number of subjects: 0
Study 16226211 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex highway environment
Number of subjects: 0
Study 16226211 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple highway environment
Number of subjects: 0
Study 14515185 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) at 24 microg/kg/h (N=850)
Number of subjects: 1690
Study 14515185 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=840)
Number of subjects: 1690
Study 14515185 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 1690
Study 10861916 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (mean dose 3.7 mg/day)
Number of subjects: 180
Study 10861916 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 180
Study 10861916 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotic agents (historical control)
Number of subjects: 180
Study 9032177 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 0
Study 9032177 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma
Number of subjects: 0
Study 9032177 — intervention group
Group type: COMPARATOR
Intervention: Asthma and COPD
Number of subjects: 0
Study 7801579 — intervention group
Group type: EXPERIMENTAL
Intervention: Bengal rose stain labeled with short‐lived 123I (123I‐BR)
Number of subjects: 201
Study 7801579 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher activities of 123I‐BR (120 MBc and higher)
Number of subjects: 201
Study 7801579 — intervention group
Group type: EXPERIMENTAL
Intervention: Single complex radionuclide examination
Number of subjects: 201
Study 7801579 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of hyperbilirubinemia
Number of subjects: 201
Study 2874825 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (20 or 40 mg)
Number of subjects: 10
Study 2874825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31636828 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopharmacotherapy‐Structured Clinical Observation (P‐SCO)
Number of subjects: 65
Study 28436580 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue antenatal steroids (AS)
Number of subjects: 96
Study 28436580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 24495273 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil hydrochloride orally disintegrating tablet (ODT) with 10 mg of ammonium glycyrrhizinate
Number of subjects: 16
Study 24495273 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil hydrochloride ODT with 50% Starlac®
Number of subjects: 16
Study 24398166 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Ji Quan: Moving for Better Balance (TJQMBB) program for 14 weeks
Number of subjects: 46
Study 24398166 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 24398166 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Ji Quan: Moving for Better Balance (TJQMBB) program
Number of subjects: 46
Study 22513296 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity risk alleles at FTO rs1421085
Number of subjects: 2075
Study 22513296 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk variants within BDNF
Number of subjects: 2075
Study 22513296 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk allele at SH2B1 rs4788099
Number of subjects: 2075
Study 22513296 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk allele at TNNI3K rs1514176
Number of subjects: 2075
Study 19365775 — intervention group
Group type: EXPERIMENTAL
Intervention: Asphalt workers
Number of subjects: 50
Study 19365775 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 50
Study 17563023 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous counseling (1 in-clinic session on all 3 behaviors every 6 months, supplemented by motivational interviewing by telephone for 18 months)
Number of subjects: 289
Study 17563023 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential counseling (addressing a new behavior every 6 months)
Number of subjects: 289
Study 17563023 — intervention group
Group type: COMPARATOR
Intervention: Usual care (1-time referral to existing group classes)
Number of subjects: 289
Study 17563023 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous counseling
Number of subjects: 289
Study 17563023 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential counseling
Number of subjects: 289
Study 17563023 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 289
Study 12719667 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin (group A)
Number of subjects: 190
Study 12719667 — intervention group
Group type: COMPARATOR
Intervention: Topical norfloxacin (group B)
Number of subjects: 190
Study 11094369 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary protraction bow appliance
Number of subjects: 29
Study 11094369 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 29
Study 8973975 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity, short duration (HS) = 70% VO2peak for 15 min
Number of subjects: 10
Study 8973975 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity, long duration (LL) = 35% VO2peak for 30 min
Number of subjects: 10
Study 8973975 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity, short duration (LS) = 35% VO2peak for 15 min
Number of subjects: 10
Study 1627281 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdermal needle electrodes (stainless steel and platinum/iridium alloy)
Number of subjects: 19
Study 6334142 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus CCNU
Number of subjects: 31
Study 6334142 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus CCNU plus LMS
Number of subjects: 31
Study 3161700 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase
Number of subjects: 302
Study 3161700 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 302
Study 29428751 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk with Lactococcus lactis NRRL B‐50571
Number of subjects: 36
Study 29428751 — intervention group
Group type: COMPARATOR
Intervention: Artificially acidified milk (Control)
Number of subjects: 36
Study 27724870 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus paclitaxel (arm A)
Number of subjects: 147
Study 27724870 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus metronomic cyclophosphamide and capecitabine (arm B)
Number of subjects: 147
Study 24417206 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine 400 mg
Number of subjects: 92
Study 24417206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 22833186 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs (overall)
Number of subjects: 19
Study 22833186 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib
Number of subjects: 19
Study 22833186 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 19
Study 20109986 — intervention group
Group type: EXPERIMENTAL
Intervention: CG care plus tobacco industry and media (IAM) messages
Number of subjects: 87
Study 20109986 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 87
Study 18545931 — intervention group
Group type: EXPERIMENTAL
Intervention: frovatriptan 2.5 mg
Number of subjects: 20
Study 16637070 — intervention group
Group type: EXPERIMENTAL
Intervention: PFTA, EMG Biofeedback, and NMES (Group 3)
Number of subjects: 30
Study 16637070 — intervention group
Group type: EXPERIMENTAL
Intervention: PFTA and EMG Biofeedback (Group 2)
Number of subjects: 30
Study 16637070 — intervention group
Group type: COMPARATOR
Intervention: PFTA (Group 1)
Number of subjects: 30
Study 14532920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem (1 gr/day)
Number of subjects: 623
Study 14532920 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin/tazobactam (3.375 gr every six hours)
Number of subjects: 623
Study 14532920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 623
Study 14532920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem and Piperacillin/tazobactam
Number of subjects: 623
Study 11035829 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation (fat supplement supplying 26% as fatty acids including DHA, 8%)
Number of subjects: 20
Study 11035829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11035829 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation
Number of subjects: 20
Study 8643248 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with the adapted esotropic target angle
Number of subjects: 305
Study 8643248 — intervention group
Group type: COMPARATOR
Intervention: Surgery with the entry angle
Number of subjects: 305
Study 1406879 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine (100 mg/kg/day for 72 hours)
Number of subjects: 83
Study 1406879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 1406879 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine
Number of subjects: 83
Study 3899674 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 28318 100 mg (9 alpha‐FHC ingestion)
Number of subjects: 0
Study 3899674 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 28318 200 mg (aldosterone infusion)
Number of subjects: 0
Study 3899674 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 28318 100 mg (furosemide ingestion)
Number of subjects: 0
Study 3899674 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 28318 300 mg (furosemide ingestion)
Number of subjects: 0
Study 3899674 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (identical doses to RU 28318)
Number of subjects: 0
Study 3899674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29274022 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 70
Study 29274022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 70
Study 29566555 — intervention group
Group type: EXPERIMENTAL
Intervention: Happiness induction
Number of subjects: 219
Study 29566555 — intervention group
Group type: COMPARATOR
Intervention: Fear induction
Number of subjects: 219
Study 29566555 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no emotion)
Number of subjects: 219
Study 29231523 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative electroacupuncture at Neiguan (PC 6), Zusanli (ST 36), and Shangjuxu (ST 37) for 20 min at 15 Hz, one day before surgery.
Number of subjects: 60
Study 29231523 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electroacupuncture).
Number of subjects: 60
Study 24121364 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecolic reconstruction
Number of subjects: 64
Study 24121364 — intervention group
Group type: COMPARATOR
Intervention: Retrocolic reconstruction
Number of subjects: 64
Study 22398153 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based parent training
Number of subjects: 104
Study 22398153 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 104
Study 20299089 — intervention group
Group type: EXPERIMENTAL
Intervention: Galardin
Number of subjects: 0
Study 20299089 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine digluconate
Number of subjects: 0
Study 18658075 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (solid food)
Number of subjects: 137
Study 18658075 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-based ketogenic diet
Number of subjects: 137
Study 18658075 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 137
Study 18658075 — intervention group
Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 137
Study 15911669 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous pinning
Number of subjects: 57
Study 15911669 — intervention group
Group type: COMPARATOR
Intervention: Immobilisation in a cast
Number of subjects: 57
Study 12839693 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-11 (25 microg/kg body weight, subcutaneously once daily for 7 to 14 days)
Number of subjects: 118
Study 12839693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 12839693 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-11
Number of subjects: 118
Study 10489789 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy
Number of subjects: 10
Study 8895208 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine
Number of subjects: 75
Study 8895208 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 75
Study 8895208 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Number of subjects: 75
Study 8895208 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 75
Study 8895208 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine
Number of subjects: 75
Study 1799467 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 58
Study 1799467 — intervention group
Group type: COMPARATOR
Intervention: Interferon
Number of subjects: 58
Study 6226488 — intervention group
Group type: EXPERIMENTAL
Intervention: NET-EN (84-day)
Number of subjects: 3172
Study 6226488 — intervention group
Group type: COMPARATOR
Intervention: DMPA
Number of subjects: 3172
Study 6226488 — intervention group
Group type: COMPARATOR
Intervention: NET-EN (60-day)
Number of subjects: 3172
Study 6226488 — intervention group
Group type: EXPERIMENTAL
Intervention: NET-EN (60-day) and NET-EN (84-day)
Number of subjects: 3172
Study 6226488 — intervention group
Group type: EXPERIMENTAL
Intervention: All three regimens
Number of subjects: 3172
Study 30663077 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 225 mg twice daily for 12 weeks
Number of subjects: 85
Study 30663077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 28935772 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib in combination with lenalidomide and dexamethasone (CRd)
Number of subjects: 0
Study 28935772 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone alone
Number of subjects: 0
Study 26287536 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine
Number of subjects: 665
Study 24062397 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib (NSAID)
Number of subjects: 896
Study 24062397 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aspirin use
Number of subjects: 896
Study 22182951 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial OMM suppression technique
Number of subjects: 21
Study 22182951 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial OMM augmentation technique
Number of subjects: 21
Study 22182951 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 21
Study 22182951 — intervention group
Group type: COMPARATOR
Intervention: Cranial OMM and sham therapy
Number of subjects: 21
Study 19377182 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation (Laerdal Virtual I.V. simulator)
Number of subjects: 40
Study 19377182 — intervention group
Group type: COMPARATOR
Intervention: Traditional (observed IV insertion on an actual patient)
Number of subjects: 40
Study 17847940 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal catheter analgesia (group A, n = 40)
Number of subjects: 80
Study 17847940 — intervention group
Group type: COMPARATOR
Intervention: Intercostal nerve block (group B, n = 40)
Number of subjects: 80
Study 15588465 — intervention group
Group type: EXPERIMENTAL
Intervention: urinary FSH (uFSH)
Number of subjects: 170
Study 15588465 — intervention group
Group type: COMPARATOR
Intervention: recombinant FSH (rFSH)
Number of subjects: 170
Study 11305826 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I - 20 mg lidocaine plus 25 microg fentanyl
Number of subjects: 30
Study 11305826 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II - 20 mg lidocaine plus 10 microg sufentanil
Number of subjects: 30
Study 11305826 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III - 10 mg lidocaine plus 10 microg sufentanil
Number of subjects: 30
Study 9604053 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar spine osteophytes in men
Number of subjects: 434
Study 9604053 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip osteophytes in women
Number of subjects: 434
Study 9604053 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis at the hip
Number of subjects: 434
Study 9604053 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis at the lumbar spine
Number of subjects: 434
Study 9604053 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis in women and men free of spinal osteoarthritis
Number of subjects: 434